CenterWatch CW World -- International Listings for Immunology/Infectious Diseases

International Clinical Trials in Immunology/Infectious Diseases

Argentina

Hepatitis C; Chronic: CHARIOT study - A Study of Induction Dosing with PEGASYS (Peginterferon alfa-2a (40KD)) and Ribavirin in Patients With Chronic Hepatitis C (CHC) Genotype-1
Buenos Aires ; Research Site:
Hepatitis C; Chronic: CHARIOT study - A Study of Induction Dosing with PEGASYS (Peginterferon alfa-2a (40KD)) and Ribavirin in Patients With Chronic Hepatitis C (CHC) Genotype-1
La Plata; Research Site:
Hepatitis C; Chronic: CHARIOT study - A Study of Induction Dosing with PEGASYS (Peginterferon alfa-2a (40KD)) and Ribavirin in Patients With Chronic Hepatitis C (CHC) Genotype-1
Rosario; Research Site:
Hepatitis C; Chronic: EAP (Expanded Access Program). A Study of PEGASYS (Peginterferon alfa-2a (40KD))Monotherapy and Combination Therapy With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC).
Buenos Aires ; Research Site:
HIV Infections: A Study of Invirase (Saquinavir)/Ritonavir in HIV-Infected Infants and Children.
Buenos Aires ; Research Site:
HIV Infections: A Study of Invirase (Saquinavir)/Ritonavir in HIV-Infected Infants and Children.
Santa Fe; Research Site:
Lupus: A Study of CellCept (Mycophenolate Mofetil) in Management of Patients With Lupus Nephritis.
Buenos Aires ; Research Site:
Lupus: A Study of CellCept (Mycophenolate Mofetil) in Management of Patients With Lupus Nephritis.
Córdoba; Research Site:
Lupus: A Study of CellCept (Mycophenolate Mofetil) in Management of Patients With Lupus Nephritis.
San Isidro; Research Site:
Lupus: A Study of CellCept (Mycophenolate Mofetil) in Management of Patients With Lupus Nephritis.
Tucuman; Research Site:
Pneumonia: A Study to Assess Beta-Lactam in the Treatment of Hospitalized Patients With Bacterial Pneumonia
Buenos Aires ; Research Site:
Pneumonia: A Study to Assess Beta-Lactam in the Treatment of Hospitalized Patients With Bacterial Pneumonia
Ciudadela; Research Site:
Pneumonia: A Study to Assess Beta-Lactam in the Treatment of Hospitalized Patients With Bacterial Pneumonia
Córdoba; Research Site:
Pneumonia: A Study to Assess Beta-Lactam in the Treatment of Hospitalized Patients With Bacterial Pneumonia
Granadero Baigorria; Research Site:
Pneumonia: A Study to Assess Beta-Lactam in the Treatment of Hospitalized Patients With Bacterial Pneumonia
Parana; Research Site:
Pneumonia: A Study to Assess Beta-Lactam in the Treatment of Hospitalized Patients With Bacterial Pneumonia
Rosario; Research Site:
Soft Tissue Infections: A Study of Beta-Lactam in Hospitalized Patients With Skin and Skin Structure Infections
Buenos Aires ; Research Site:
Soft Tissue Infections: A Study of Beta-Lactam in Hospitalized Patients With Skin and Skin Structure Infections
Ciudadela; Research Site:
Soft Tissue Infections: A Study of Beta-Lactam in Hospitalized Patients With Skin and Skin Structure Infections
Córdoba; Research Site:
Soft Tissue Infections: A Study of Beta-Lactam in Hospitalized Patients With Skin and Skin Structure Infections
Granadero Baigorria; Research Site:
Soft Tissue Infections: A Study of Beta-Lactam in Hospitalized Patients With Skin and Skin Structure Infections
Neuquen; Research Site:
Soft Tissue Infections: A Study of Beta-Lactam in Hospitalized Patients With Skin and Skin Structure Infections
Palomar; Research Site:
Soft Tissue Infections: A Study of Beta-Lactam in Hospitalized Patients With Skin and Skin Structure Infections
Parana; Research Site:
Soft Tissue Infections: A Study of Beta-Lactam in Hospitalized Patients With Skin and Skin Structure Infections
Rosario; Research Site:
Soft Tissue Infections: A Study of Beta-Lactam in Hospitalized Patients With Skin and Skin Structure Infections
Santa Fe; Research Site:
Systemic Lupus Erythematosus: A Study of Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus.
Buenos Aires ; Research Site:
Systemic Lupus Erythematosus: A Study of Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus.
Córdoba; Research Site:
Systemic Lupus Erythematosus: A Study of Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus.
San Juan; Research Site:
Systemic Lupus Erythematosus: A Study of Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus.
San Miguel De Tucuman; Research Site:
Systemic Lupus Erythematosus: A Study of Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus.
Tucuman; Research Site:
Systemic Lupus Erythematosus: A Study of Ocrelizumab in Patients With Systemic Lupus Erythematosus.
Buenos Aires ; Research Site:
Systemic Lupus Erythematosus: A Study of Ocrelizumab in Patients With Systemic Lupus Erythematosus.
Córdoba; Research Site:
Systemic Lupus Erythematosus: A Study of Ocrelizumab in Patients With Systemic Lupus Erythematosus.
San Juan; Research Site:
Systemic Lupus Erythematosus: A Study of Ocrelizumab in Patients With Systemic Lupus Erythematosus.
San Miguel De Tucuman; Research Site:
Systemic Lupus Erythematosus: A Study of Ocrelizumab in Patients With Systemic Lupus Erythematosus.
Tucuman; Research Site:

Australia

Cytomegalovirus Infections: A Study of Valcyte (Valganciclovir) Syrup Formulation in Pediatric Solid Organ Transplant Recipients
Parkville; Research Site:
Cytomegalovirus Infections: IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients
Melbourne; Research Site:
Cytomegalovirus Infections: IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients
Parkville; Research Site:
Cytomegalovirus Infections: IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients
Sydney; Research Site:
Cytomegalovirus Infections: VICTOR Study - A Study of Valcyte (Valganciclovir po) Compared to Ganciclovir iv in Patients With Cytomegalovirus (CMV) Disease Who Are Solid Organ Transplant Recipients
Chermside; Research Site:
Cytomegalovirus Infections: VICTOR Study - A Study of Valcyte (Valganciclovir po) Compared to Ganciclovir iv in Patients With Cytomegalovirus (CMV) Disease Who Are Solid Organ Transplant Recipients
Darlinghurst; Research Site:
Cytomegalovirus Infections: VICTOR Study - A Study of Valcyte (Valganciclovir po) Compared to Ganciclovir iv in Patients With Cytomegalovirus (CMV) Disease Who Are Solid Organ Transplant Recipients
Sydney; Research Site:
Cytomegalovirus Infections: VICTOR Study - A Study of Valcyte (Valganciclovir po) Compared to Ganciclovir iv in Patients With Cytomegalovirus (CMV) Disease Who Are Solid Organ Transplant Recipients
Woolloongabba; Research Site:
Hepatitis B: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B (CHB).
Brisbane; Research Site:
Hepatitis B: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B (CHB).
Fitzroy; Research Site:
Hepatitis C; Chronic: A Study of HCV Polymerase Inhibitor Pro-Drug in Combination With PEGASYS Plus COPEGUS Compared With PEGASYS Plus COPEGUS in Patients With Chronic Hepatitis C Genotype 1 Infection.
Adelaide; Research Site:
Hepatitis C; Chronic: A Study of HCV Polymerase Inhibitor Pro-Drug in Combination With PEGASYS Plus COPEGUS Compared With PEGASYS Plus COPEGUS in Patients With Chronic Hepatitis C Genotype 1 Infection.
Brisbane; Research Site:
Hepatitis C; Chronic: A Study of HCV Polymerase Inhibitor Pro-Drug in Combination With PEGASYS Plus COPEGUS Compared With PEGASYS Plus COPEGUS in Patients With Chronic Hepatitis C Genotype 1 Infection.
Melbourne; Research Site:
Hepatitis C; Chronic: A Study of HCV Polymerase Inhibitor Pro-Drug in Combination With PEGASYS Plus COPEGUS Compared With PEGASYS Plus COPEGUS in Patients With Chronic Hepatitis C Genotype 1 Infection.
Sydney; Research Site:
Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Administered Alone or in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Who Have Participated in Previous PEGASYS Trials.
Adelaide; Research Site:
Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Administered Alone or in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Who Have Participated in Previous PEGASYS Trials.
Brisbane; Research Site:
Hepatitis C; Chronic: ACCELERATE Study - A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC) Infection.
Adelaide; Research Site:
Hepatitis C; Chronic: ACCELERATE Study - A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC) Infection.
Brisbane; Research Site:
Hepatitis C; Chronic: ACCELERATE Study - A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC) Infection.
Kingswood; Research Site:
Hepatitis C; Chronic: ACCELERATE Study - A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC) Infection.
Melbourne; Research Site:
Hepatitis C; Chronic: ACCELERATE Study - A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC) Infection.
Woolloongabba; Research Site:
Hepatitis C; Chronic: CHARIOT study - A Study of Induction Dosing with PEGASYS (Peginterferon alfa-2a (40KD)) and Ribavirin in Patients With Chronic Hepatitis C (CHC) Genotype-1
Adelaide; Research Site:
Hepatitis C; Chronic: CHARIOT study - A Study of Induction Dosing with PEGASYS (Peginterferon alfa-2a (40KD)) and Ribavirin in Patients With Chronic Hepatitis C (CHC) Genotype-1
Bankstown; Research Site:
Hepatitis C; Chronic: CHARIOT study - A Study of Induction Dosing with PEGASYS (Peginterferon alfa-2a (40KD)) and Ribavirin in Patients With Chronic Hepatitis C (CHC) Genotype-1
Box Hill; Research Site:
Hepatitis C; Chronic: CHARIOT study - A Study of Induction Dosing with PEGASYS (Peginterferon alfa-2a (40KD)) and Ribavirin in Patients With Chronic Hepatitis C (CHC) Genotype-1
Brisbane; Research Site:
Hepatitis C; Chronic: CHARIOT study - A Study of Induction Dosing with PEGASYS (Peginterferon alfa-2a (40KD)) and Ribavirin in Patients With Chronic Hepatitis C (CHC) Genotype-1
Cottontree; Research Site:
Hepatitis C; Chronic: CHARIOT study - A Study of Induction Dosing with PEGASYS (Peginterferon alfa-2a (40KD)) and Ribavirin in Patients With Chronic Hepatitis C (CHC) Genotype-1
Darlinghurst; Research Site:
Hepatitis C; Chronic: CHARIOT study - A Study of Induction Dosing with PEGASYS (Peginterferon alfa-2a (40KD)) and Ribavirin in Patients With Chronic Hepatitis C (CHC) Genotype-1
Douglas; Research Site:
Hepatitis C; Chronic: CHARIOT study - A Study of Induction Dosing with PEGASYS (Peginterferon alfa-2a (40KD)) and Ribavirin in Patients With Chronic Hepatitis C (CHC) Genotype-1
Fitzroy; Research Site:
Hepatitis C; Chronic: CHARIOT study - A Study of Induction Dosing with PEGASYS (Peginterferon alfa-2a (40KD)) and Ribavirin in Patients With Chronic Hepatitis C (CHC) Genotype-1
Fremantle; Research Site:
Hepatitis C; Chronic: CHARIOT study - A Study of Induction Dosing with PEGASYS (Peginterferon alfa-2a (40KD)) and Ribavirin in Patients With Chronic Hepatitis C (CHC) Genotype-1
Geelong; Research Site:
Hepatitis C; Chronic: CHARIOT study - A Study of Induction Dosing with PEGASYS (Peginterferon alfa-2a (40KD)) and Ribavirin in Patients With Chronic Hepatitis C (CHC) Genotype-1
Kingswood; Research Site:
Hepatitis C; Chronic: CHARIOT study - A Study of Induction Dosing with PEGASYS (Peginterferon alfa-2a (40KD)) and Ribavirin in Patients With Chronic Hepatitis C (CHC) Genotype-1
Lismore; Research Site:
Hepatitis C; Chronic: CHARIOT study - A Study of Induction Dosing with PEGASYS (Peginterferon alfa-2a (40KD)) and Ribavirin in Patients With Chronic Hepatitis C (CHC) Genotype-1
Liverpool; Research Site:
Hepatitis C; Chronic: CHARIOT study - A Study of Induction Dosing with PEGASYS (Peginterferon alfa-2a (40KD)) and Ribavirin in Patients With Chronic Hepatitis C (CHC) Genotype-1
Melbourne; Research Site:
Hepatitis C; Chronic: CHARIOT study - A Study of Induction Dosing with PEGASYS (Peginterferon alfa-2a (40KD)) and Ribavirin in Patients With Chronic Hepatitis C (CHC) Genotype-1
Miranda; Research Site:
Hepatitis C; Chronic: CHARIOT study - A Study of Induction Dosing with PEGASYS (Peginterferon alfa-2a (40KD)) and Ribavirin in Patients With Chronic Hepatitis C (CHC) Genotype-1
Nedlands; Research Site:
Hepatitis C; Chronic: CHARIOT study - A Study of Induction Dosing with PEGASYS (Peginterferon alfa-2a (40KD)) and Ribavirin in Patients With Chronic Hepatitis C (CHC) Genotype-1
New Lambton Heights; Research Site:
Hepatitis C; Chronic: CHARIOT study - A Study of Induction Dosing with PEGASYS (Peginterferon alfa-2a (40KD)) and Ribavirin in Patients With Chronic Hepatitis C (CHC) Genotype-1
Parkville; Research Site:
Hepatitis C; Chronic: CHARIOT study - A Study of Induction Dosing with PEGASYS (Peginterferon alfa-2a (40KD)) and Ribavirin in Patients With Chronic Hepatitis C (CHC) Genotype-1
Perth; Research Site:
Hepatitis C; Chronic: CHARIOT study - A Study of Induction Dosing with PEGASYS (Peginterferon alfa-2a (40KD)) and Ribavirin in Patients With Chronic Hepatitis C (CHC) Genotype-1
Sydney; Research Site:
Hepatitis C; Chronic: CHARIOT study - A Study of Induction Dosing with PEGASYS (Peginterferon alfa-2a (40KD)) and Ribavirin in Patients With Chronic Hepatitis C (CHC) Genotype-1
Victoria; Research Site:
Hepatitis C; Chronic: CHARIOT study - A Study of Induction Dosing with PEGASYS (Peginterferon alfa-2a (40KD)) and Ribavirin in Patients With Chronic Hepatitis C (CHC) Genotype-1
Woden; Research Site:
Hepatitis C; Chronic: CHARIOT study - A Study of Induction Dosing with PEGASYS (Peginterferon alfa-2a (40KD)) and Ribavirin in Patients With Chronic Hepatitis C (CHC) Genotype-1
Wollongong; Research Site:
Hepatitis C; Chronic: CHARIOT study - A Study of Induction Dosing with PEGASYS (Peginterferon alfa-2a (40KD)) and Ribavirin in Patients With Chronic Hepatitis C (CHC) Genotype-1
Woolloongabba; Research Site:
Hepatitis C; Chronic: EAP (Expanded Access Program). A Study of PEGASYS (Peginterferon alfa-2a (40KD))Monotherapy and Combination Therapy With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC).
Dee Why; Research Site:
HIV Infections: BLQ Study: A Study of a Protease Inhibitor With Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With HIV-1.
Brisbane; Research Site:
HIV Infections: BLQ Study: A Study of a Protease Inhibitor With Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With HIV-1.
Carlton; Research Site:
HIV Infections: BLQ Study: A Study of a Protease Inhibitor With Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With HIV-1.
Liverpool; Research Site:
HIV Infections: BLQ Study: A Study of a Protease Inhibitor With Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With HIV-1.
Melbourne; Research Site:
HIV Infections: BLQ Study: A Study of a Protease Inhibitor With Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With HIV-1.
South Yarra; Research Site:
HIV Infections: BLQ Study: A Study of a Protease Inhibitor With Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With HIV-1.
Sydney; Research Site:
HIV Infections: OPTIONS Study: A Study of Three Delivery Mechanisms for Fuzeon.
Adelaide; Research Site:
HIV Infections: OPTIONS Study: A Study of Three Delivery Mechanisms for Fuzeon.
Brisbane; Research Site:
HIV Infections: OPTIONS Study: A Study of Three Delivery Mechanisms for Fuzeon.
Carlton; Research Site:
HIV Infections: OPTIONS Study: A Study of Three Delivery Mechanisms for Fuzeon.
Melbourne; Research Site:
HIV Infections: OPTIONS Study: A Study of Three Delivery Mechanisms for Fuzeon.
South Yarra; Research Site:
HIV Infections: OPTIONS Study: A Study of Three Delivery Mechanisms for Fuzeon.
Sydney; Research Site:
HIV Infections: OPTIONS Study: A Study of Three Delivery Mechanisms for Fuzeon.
Westmead; Research Site:
Idiopathic Thrombocytopenic Purpura (ITP): A Study of MabThera (Rituximab) in Patients With Idiopathic Thrombocytopenic Purpura.
Adelaide; Research Site:
Idiopathic Thrombocytopenic Purpura (ITP): A Study of MabThera (Rituximab) in Patients With Idiopathic Thrombocytopenic Purpura.
Frankston; Research Site:
Idiopathic Thrombocytopenic Purpura (ITP): A Study of MabThera (Rituximab) in Patients With Idiopathic Thrombocytopenic Purpura.
Gosford; Research Site:
Idiopathic Thrombocytopenic Purpura (ITP): A Study of MabThera (Rituximab) in Patients With Idiopathic Thrombocytopenic Purpura.
Malvern; Research Site:
Idiopathic Thrombocytopenic Purpura (ITP): A Study of MabThera (Rituximab) in Patients With Idiopathic Thrombocytopenic Purpura.
Melbourne; Research Site:
Idiopathic Thrombocytopenic Purpura (ITP): A Study of MabThera (Rituximab) in Patients With Idiopathic Thrombocytopenic Purpura.
Parkville; Research Site:
Idiopathic Thrombocytopenic Purpura (ITP): A Study of MabThera (Rituximab) in Patients With Idiopathic Thrombocytopenic Purpura.
Randwick; Research Site:
Idiopathic Thrombocytopenic Purpura (ITP): A Study of MabThera (Rituximab) in Patients With Idiopathic Thrombocytopenic Purpura.
Sydney; Research Site:
Idiopathic Thrombocytopenic Purpura (ITP): A Study of MabThera (Rituximab) in Patients With Idiopathic Thrombocytopenic Purpura.
Westmead; Research Site:
Idiopathic Thrombocytopenic Purpura (ITP): A Study of MabThera (Rituximab) in Patients With Idiopathic Thrombocytopenic Purpura.
Woolloongabba; Research Site:
Lupus: A Study of CellCept (Mycophenolate Mofetil) in Management of Patients With Lupus Nephritis.
Parkville; Research Site:

Austria

Cytomegalovirus Infections: A Study of Valcyte (Valganciclovir) CMV Prophylaxis After Renal Transplantation
Innsbruck; Research Site:
Cytomegalovirus Infections: A Study of Valcyte (Valganciclovir) CMV Prophylaxis After Renal Transplantation
Wien; Research Site:
Cytomegalovirus Infections: VICTOR Study - A Study of Valcyte (Valganciclovir po) Compared to Ganciclovir iv in Patients With Cytomegalovirus (CMV) Disease Who Are Solid Organ Transplant Recipients
Wien; Research Site:
Hepatitis B: A Study of PEGASYS plus Ribavirin Combination Therapy in Patients with HBeAg-Negative Chronic Hepatitis B Infection
Innsbruck; Research Site:
Hepatitis B: A Study of PEGASYS plus Ribavirin Combination Therapy in Patients with HBeAg-Negative Chronic Hepatitis B Infection
Vienna; Research Site:
Hepatitis C; Chronic: A Study of HCV Polymerase Inhibitor Pro-Drug in Combination With PEGASYS Plus COPEGUS Compared With PEGASYS Plus COPEGUS in Patients With Chronic Hepatitis C Genotype 1 Infection.
Wien; Research Site:
Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC).
Gratwein; Research Site:
Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC).
Graz; Research Site:
Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC).
Innsbruck; Research Site:
Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC).
Krems; Research Site:
Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC).
Linz; Research Site:
Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC).
Oberndorf; Research Site:
Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC).
Oberpullendorf; Research Site:
Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC).
Ried-Innkreis; Research Site:
Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC).
Salzburg; Research Site:
Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC).
Wels; Research Site:
Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC).
Wien; Research Site:
Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC).
Wiener Neustadt; Research Site:
Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Ribavirin in Patients With Chronic Hepatitis C (CHC), Genotype 2 or 3
Gratwein; Research Site:
Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Ribavirin in Patients With Chronic Hepatitis C (CHC), Genotype 2 or 3
Graz; Research Site:
Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Ribavirin in Patients With Chronic Hepatitis C (CHC), Genotype 2 or 3
Innsbruck; Research Site:
Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Ribavirin in Patients With Chronic Hepatitis C (CHC), Genotype 2 or 3
Krems; Research Site:
Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Ribavirin in Patients With Chronic Hepatitis C (CHC), Genotype 2 or 3
Linz; Research Site:
Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Ribavirin in Patients With Chronic Hepatitis C (CHC), Genotype 2 or 3
Oberndorf; Research Site:
Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Ribavirin in Patients With Chronic Hepatitis C (CHC), Genotype 2 or 3
Oberpullendorf; Research Site:
Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Ribavirin in Patients With Chronic Hepatitis C (CHC), Genotype 2 or 3
Ried-Innkreis; Research Site:
Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Ribavirin in Patients With Chronic Hepatitis C (CHC), Genotype 2 or 3
Salzburg; Research Site:
Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Ribavirin in Patients With Chronic Hepatitis C (CHC), Genotype 2 or 3
Villach; Research Site:
Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Ribavirin in Patients With Chronic Hepatitis C (CHC), Genotype 2 or 3
Vöcklabruck; Research Site:
Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Ribavirin in Patients With Chronic Hepatitis C (CHC), Genotype 2 or 3
Wels; Research Site:
Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Ribavirin in Patients With Chronic Hepatitis C (CHC), Genotype 2 or 3
Wien; Research Site:
Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Ribavirin in Patients With Chronic Hepatitis C (CHC), Genotype 2 or 3
Wiener Neustadt; Research Site:
Hepatitis C; Chronic: EAP (Expanded Access Program). A Study of PEGASYS (Peginterferon alfa-2a (40KD))Monotherapy and Combination Therapy With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC).
Wien; Research Site:
Hepatitis C; Chronic: HELPS study - A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC) and End-Stage Renal Disease
Graz; Research Site:
Hepatitis C; Chronic: HELPS study - A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC) and End-Stage Renal Disease
Wien; Research Site:

Bangladesh

Hepatitis C; Chronic: A Study of Roferon-A (Interferon Alfa-2a) in Patients With Chronic Hepatitis C
Dhaka; Research Site:
Hepatitis C; Chronic: EAP (Expanded Access Program). A Study of PEGASYS (Peginterferon alfa-2a (40KD))Monotherapy and Combination Therapy With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC).
Dhaka; Research Site:

Belgium

Cytomegalovirus Infections: IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients
Bruxelles; Research Site:
Cytomegalovirus Infections: IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients
Gent; Research Site:
Cytomegalovirus Infections: IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients
Leuven; Research Site:
Cytomegalovirus Infections: VICTOR Study - A Study of Valcyte (Valganciclovir po) Compared to Ganciclovir iv in Patients With Cytomegalovirus (CMV) Disease Who Are Solid Organ Transplant Recipients
Bruxelles; Research Site:
Hepatitis C; Chronic: A Study of Combination Therapy With PEGASYS (Peginterferon alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response.
Antwerpen; Research Site:
Hepatitis C; Chronic: A Study of Combination Therapy With PEGASYS (Peginterferon alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response.
Bruxelles; Research Site:
Hepatitis C; Chronic: A Study of Combination Therapy With PEGASYS (Peginterferon alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response.
Gent; Research Site:
Hepatitis C; Chronic: A Study of Combination Therapy With PEGASYS (Peginterferon alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response.
Kortrijk; Research Site:
Hepatitis C; Chronic: A Study of Combination Therapy With PEGASYS (Peginterferon alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response.
Liege; Research Site:
Hepatitis C; Chronic: A Study of Induction Dosing With PEGASYS (Peginterferon alfa-2a (40KD)) Plus Copegus in Treatment-Naive Patients With Chronic Hepatitis C.
Bruxelles; Research Site:
Hepatitis C; Chronic: A Study of Induction Dosing With PEGASYS (Peginterferon alfa-2a (40KD)) Plus Copegus in Treatment-Naive Patients With Chronic Hepatitis C.
Gent; Research Site:
Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Ribavirin, With or Without Amantadine, in Treatment-Naive or Relapsing Patients With Chronic Hepatitis C (CHC)
Antwerpen; Research Site:
Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Ribavirin, With or Without Amantadine, in Treatment-Naive or Relapsing Patients With Chronic Hepatitis C (CHC)
Assebroek; Research Site:
Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Ribavirin, With or Without Amantadine, in Treatment-Naive or Relapsing Patients With Chronic Hepatitis C (CHC)
Brugge; Research Site:
Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Ribavirin, With or Without Amantadine, in Treatment-Naive or Relapsing Patients With Chronic Hepatitis C (CHC)
Bruxelles; Research Site:
Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Ribavirin, With or Without Amantadine, in Treatment-Naive or Relapsing Patients With Chronic Hepatitis C (CHC)
Charleroi; Research Site:
Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Ribavirin, With or Without Amantadine, in Treatment-Naive or Relapsing Patients With Chronic Hepatitis C (CHC)
Edegem; Research Site:
Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Ribavirin, With or Without Amantadine, in Treatment-Naive or Relapsing Patients With Chronic Hepatitis C (CHC)
Genk; Research Site:
Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Ribavirin, With or Without Amantadine, in Treatment-Naive or Relapsing Patients With Chronic Hepatitis C (CHC)
Gent; Research Site:
Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Ribavirin, With or Without Amantadine, in Treatment-Naive or Relapsing Patients With Chronic Hepatitis C (CHC)
Gilly; Research Site:
Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Ribavirin, With or Without Amantadine, in Treatment-Naive or Relapsing Patients With Chronic Hepatitis C (CHC)
Haine-Saint-Paul; Research Site:
Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Ribavirin, With or Without Amantadine, in Treatment-Naive or Relapsing Patients With Chronic Hepatitis C (CHC)
Huy; Research Site:
Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Ribavirin, With or Without Amantadine, in Treatment-Naive or Relapsing Patients With Chronic Hepatitis C (CHC)
Kortrijk; Research Site:
Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Ribavirin, With or Without Amantadine, in Treatment-Naive or Relapsing Patients With Chronic Hepatitis C (CHC)
La Louviere; Research Site:
Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Ribavirin, With or Without Amantadine, in Treatment-Naive or Relapsing Patients With Chronic Hepatitis C (CHC)
Leuven; Research Site:
Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Ribavirin, With or Without Amantadine, in Treatment-Naive or Relapsing Patients With Chronic Hepatitis C (CHC)
Liege; Research Site:
Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Ribavirin, With or Without Amantadine, in Treatment-Naive or Relapsing Patients With Chronic Hepatitis C (CHC)
Mons; Research Site:
Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Ribavirin, With or Without Amantadine, in Treatment-Naive or Relapsing Patients With Chronic Hepatitis C (CHC)
Namur; Research Site:
Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Ribavirin, With or Without Amantadine, in Treatment-Naive or Relapsing Patients With Chronic Hepatitis C (CHC)
Roeselare; Research Site:
Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Ribavirin, With or Without Amantadine, in Treatment-Naive or Relapsing Patients With Chronic Hepatitis C (CHC)
Seraing; Research Site:
Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Ribavirin, With or Without Amantadine, in Treatment-Naive or Relapsing Patients With Chronic Hepatitis C (CHC)
Tournai; Research Site:
Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Ribavirin, With or Without Amantadine, in Treatment-Naive or Relapsing Patients With Chronic Hepatitis C (CHC)
Verviers; Research Site:
Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Ribavirin, With or Without Amantadine, in Treatment-Naive or Relapsing Patients With Chronic Hepatitis C (CHC)
Yvoir; Research Site:
Hepatitis C; Chronic: A Study of Roferon-A (Interferon Alfa-2a) in Patients With Chronic Hepatitis C
Bruxelles; Research Site:
Hepatitis C; Chronic: BeTTy study - A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Combination Therapy in Patients With Chronic Hepatitis C (CHC)
Bruxelles; Research Site:
Hepatitis C; Chronic: EAP (Expanded Access Program). A Study of PEGASYS (Peginterferon alfa-2a (40KD))Monotherapy and Combination Therapy With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC).
Bruxelles; Research Site:
Hepatitis C; Chronic: PERFECT Study - A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC) and Human Immunodeficiency Virus (HIV) Co-infection, Not Responding to PEGASYS Plus Ribavirin
Bruxelles; Research Site:
Hepatitis C; Chronic: PERFECT Study - A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC) and Human Immunodeficiency Virus (HIV) Co-infection, Not Responding to PEGASYS Plus Ribavirin
Charleroi; Research Site:
Hepatitis C; Chronic: PERFECT Study - A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC) and Human Immunodeficiency Virus (HIV) Co-infection, Not Responding to PEGASYS Plus Ribavirin
Edegem; Research Site:
Hepatitis C; Chronic: PERFECT Study - A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC) and Human Immunodeficiency Virus (HIV) Co-infection, Not Responding to PEGASYS Plus Ribavirin
Gent; Research Site:
Hepatitis C; Chronic: PERFECT Study - A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC) and Human Immunodeficiency Virus (HIV) Co-infection, Not Responding to PEGASYS Plus Ribavirin
Leuven; Research Site:
Hepatitis C; Chronic: PERFECT Study - A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC) and Human Immunodeficiency Virus (HIV) Co-infection, Not Responding to PEGASYS Plus Ribavirin
Liege; Research Site:
Hepatitis C; Chronic: PINGU study - A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Ribavirin in Early Non-Responder Patients With Chronic Hepatitis C (CHC) Genotype 1/4/5/6
Antwerpen; Research Site:
Hepatitis C; Chronic: PINGU study - A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Ribavirin in Early Non-Responder Patients With Chronic Hepatitis C (CHC) Genotype 1/4/5/6
Brugge; Research Site:
Hepatitis C; Chronic: PINGU study - A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Ribavirin in Early Non-Responder Patients With Chronic Hepatitis C (CHC) Genotype 1/4/5/6
Bruxelles; Research Site:
Hepatitis C; Chronic: PINGU study - A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Ribavirin in Early Non-Responder Patients With Chronic Hepatitis C (CHC) Genotype 1/4/5/6
Charleroi; Research Site:
Hepatitis C; Chronic: PINGU study - A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Ribavirin in Early Non-Responder Patients With Chronic Hepatitis C (CHC) Genotype 1/4/5/6
Edegem; Research Site:
Hepatitis C; Chronic: PINGU study - A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Ribavirin in Early Non-Responder Patients With Chronic Hepatitis C (CHC) Genotype 1/4/5/6
Gent; Research Site:
Hepatitis C; Chronic: PINGU study - A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Ribavirin in Early Non-Responder Patients With Chronic Hepatitis C (CHC) Genotype 1/4/5/6
Gilly; Research Site:
Hepatitis C; Chronic: PINGU study - A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Ribavirin in Early Non-Responder Patients With Chronic Hepatitis C (CHC) Genotype 1/4/5/6
Haine-Saint-Paul; Research Site:
Hepatitis C; Chronic: PINGU study - A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Ribavirin in Early Non-Responder Patients With Chronic Hepatitis C (CHC) Genotype 1/4/5/6
Kortrijk; Research Site:
Hepatitis C; Chronic: PINGU study - A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Ribavirin in Early Non-Responder Patients With Chronic Hepatitis C (CHC) Genotype 1/4/5/6
Leuven; Research Site:
Hepatitis C; Chronic: PINGU study - A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Ribavirin in Early Non-Responder Patients With Chronic Hepatitis C (CHC) Genotype 1/4/5/6
Liege; Research Site:
Hepatitis C; Chronic: PINGU study - A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Ribavirin in Early Non-Responder Patients With Chronic Hepatitis C (CHC) Genotype 1/4/5/6
Namur; Research Site:
Hepatitis C; Chronic: PINGU study - A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Ribavirin in Early Non-Responder Patients With Chronic Hepatitis C (CHC) Genotype 1/4/5/6
Roeselare; Research Site:
Hepatitis C; Chronic: PINGU study - A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Ribavirin in Early Non-Responder Patients With Chronic Hepatitis C (CHC) Genotype 1/4/5/6
Yvoir; Research Site:
Hepatitis C; Chronic: REPEAT study - A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Therapy in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Who Did Not Respond to Previous PegIntron (Peginterferon alfa-2b (12KD))/Ribavirin Combination Therapy
Leuven; Research Site:
Hepatitis C; Chronic: REPEAT study - A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Therapy in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Who Did Not Respond to Previous PegIntron (Peginterferon alfa-2b (12KD))/Ribavirin Combination Therapy
Gent; Research Site:
Hepatitis C; Chronic: REPEAT study - A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Therapy in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Who Did Not Respond to Previous PegIntron (Peginterferon alfa-2b (12KD))/Ribavirin Combination Therapy
Bruxelles; Research Site:
HIV Infections: A Study to Assess the Safety of Fuzeon (Enfuvirtide) in Combination with Oral Antiretroviral Agents in Patients with Advanced Human Immunodeficiency Virus (HIV) Disease, Unable to Construct a Viable Treatment Regimen
Zaventem; Research Site:
HIV Infections: A Study to Evaluate the Safety and Tolerability of Fuzeon (Enfuvirtide) in Combination With Antiretroviral Agents in Patients With Advanced Human Immunodeficiency Virus (HIV) Infection, Unable to Construct a Viable Treatment Regimen
Bruxelles; Research Site:
Influenza: A Study of Tamiflu (Oseltamivir) for the Seasonal Prophylaxis of Influenza in Immunocompromised Patients.
Aalst; Research Site:
Influenza: A Study of Tamiflu (Oseltamivir) for the Seasonal Prophylaxis of Influenza in Immunocompromised Patients.
Bruxelles; Research Site:
Influenza: A Study of Tamiflu (Oseltamivir) for the Seasonal Prophylaxis of Influenza in Immunocompromised Patients.
Edegem; Research Site:
Influenza: A Study of Tamiflu (Oseltamivir) for the Seasonal Prophylaxis of Influenza in Immunocompromised Patients.
Leuven; Research Site:
Influenza: A Study of Tamiflu (Oseltamivir) for Treatment of Influenza in Immunocompromised Patients.
Aalst; Research Site:
Influenza: A Study of Tamiflu (Oseltamivir) for Treatment of Influenza in Immunocompromised Patients.
Bruxelles; Research Site:
Influenza: A Study of Tamiflu (Oseltamivir) for Treatment of Influenza in Immunocompromised Patients.
Leuven; Research Site:
Lupus: A Study of CellCept (Mycophenolate Mofetil) in Management of Patients With Lupus Nephritis.
Bruxelles; Research Site:
Lupus: A Study of CellCept (Mycophenolate Mofetil) in Management of Patients With Lupus Nephritis.
Liege; Research Site:

Bosnia and Herzegovina

Hepatitis C; Chronic: CEE study - A Study of PEGASYS (Peginterferon alfa-2a (40KD)) and COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC)
Sarajevo; Research Site:

Brazil

Atopic Dermatitis: A Study of Protopic (Tacrolimus) Ointment in Children With Atopic Dermatitis
Belo Horizonte; Research Site:
Atopic Dermatitis: A Study of Protopic (Tacrolimus) Ointment in Children With Atopic Dermatitis
Guarulhos; Research Site:
Atopic Dermatitis: A Study of Protopic (Tacrolimus) Ointment in Children With Atopic Dermatitis
Porto Alegre; Research Site:
Atopic Dermatitis: A Study of Protopic (Tacrolimus) Ointment in Children With Atopic Dermatitis
Sao Paulo; Research Site:
Cytomegalovirus Infections: IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients
Campinas; Research Site:
Cytomegalovirus Infections: IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients
Porto Alegre; Research Site:
Cytomegalovirus Infections: IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients
Sao Paulo; Research Site:
Cytomegalovirus Infections: VICTOR Study - A Study of Valcyte (Valganciclovir po) Compared to Ganciclovir iv in Patients With Cytomegalovirus (CMV) Disease Who Are Solid Organ Transplant Recipients
Campinas; Research Site:
Cytomegalovirus Infections: VICTOR Study - A Study of Valcyte (Valganciclovir po) Compared to Ganciclovir iv in Patients With Cytomegalovirus (CMV) Disease Who Are Solid Organ Transplant Recipients
Porto Alegre; Research Site:
Cytomegalovirus Infections: VICTOR Study - A Study of Valcyte (Valganciclovir po) Compared to Ganciclovir iv in Patients With Cytomegalovirus (CMV) Disease Who Are Solid Organ Transplant Recipients
Sao Paulo; Research Site:
Hepatitis B: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B (CHB).
Campinas; Research Site:
Hepatitis B: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B (CHB).
Ribeirăo Preto; Research Site:
Hepatitis B: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B (CHB).
Salvador; Research Site:
Hepatitis B: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B (CHB).
Santo Andre; Research Site:
Hepatitis B: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B (CHB).
Sao Paulo; Research Site:
Hepatitis C; Chronic: A Study of Induction Dosing With PEGASYS (Peginterferon alfa-2a (40KD)) Plus Copegus in Treatment-Naive Patients With Chronic Hepatitis C.
Caixa; Research Site:
Hepatitis C; Chronic: A Study of Induction Dosing With PEGASYS (Peginterferon alfa-2a (40KD)) Plus Copegus in Treatment-Naive Patients With Chronic Hepatitis C.
Campinas; Research Site:
Hepatitis C; Chronic: A Study of Induction Dosing With PEGASYS (Peginterferon alfa-2a (40KD)) Plus Copegus in Treatment-Naive Patients With Chronic Hepatitis C.
Juiz De Fora; Research Site:
Hepatitis C; Chronic: A Study of Induction Dosing With PEGASYS (Peginterferon alfa-2a (40KD)) Plus Copegus in Treatment-Naive Patients With Chronic Hepatitis C.
Porto Alegre; Research Site:
Hepatitis C; Chronic: A Study of Induction Dosing With PEGASYS (Peginterferon alfa-2a (40KD)) Plus Copegus in Treatment-Naive Patients With Chronic Hepatitis C.
Salvador; Research Site:
Hepatitis C; Chronic: A Study of Induction Dosing With PEGASYS (Peginterferon alfa-2a (40KD)) Plus Copegus in Treatment-Naive Patients With Chronic Hepatitis C.
Sao Jose do Rio Preto; Research Site:
Hepatitis C; Chronic: A Study of Induction Dosing With PEGASYS (Peginterferon alfa-2a (40KD)) Plus Copegus in Treatment-Naive Patients With Chronic Hepatitis C.
Sao Paulo; Research Site:
Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Administered Alone or in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Who Have Participated in Previous PEGASYS Trials.
Ribeirăo Preto; Research Site:
Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Administered Alone or in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Who Have Participated in Previous PEGASYS Trials.
Salvador; Research Site:
Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Administered Alone or in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Who Have Participated in Previous PEGASYS Trials.
Sao Paulo; Research Site:
Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) and COPEGUS (Ribavirin) Combination Therapy in Patients With Chronic Hepatitis C (CHC) and Various Degrees of Renal Impairment.
Sao Paulo; Research Site:
Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) plus Ribavirin, With or Without Amantidine, in Non-Responding or Relapsing Patients With Chronic Hepatitis C (CHC)
Belo Horizonte; Research Site:
Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) plus Ribavirin, With or Without Amantidine, in Non-Responding or Relapsing Patients With Chronic Hepatitis C (CHC)
Botucatu; Research Site:
Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) plus Ribavirin, With or Without Amantidine, in Non-Responding or Relapsing Patients With Chronic Hepatitis C (CHC)
Campinas; Research Site:
Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) plus Ribavirin, With or Without Amantidine, in Non-Responding or Relapsing Patients With Chronic Hepatitis C (CHC)
Curitiba; Research Site:
Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) plus Ribavirin, With or Without Amantidine, in Non-Responding or Relapsing Patients With Chronic Hepatitis C (CHC)
Goiania; Research Site:
Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) plus Ribavirin, With or Without Amantidine, in Non-Responding or Relapsing Patients With Chronic Hepatitis C (CHC)
Porto Alegre; Research Site:
Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) plus Ribavirin, With or Without Amantidine, in Non-Responding or Relapsing Patients With Chronic Hepatitis C (CHC)
Recife; Research Site:
Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) plus Ribavirin, With or Without Amantidine, in Non-Responding or Relapsing Patients With Chronic Hepatitis C (CHC)
Salvador; Research Site:
Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) plus Ribavirin, With or Without Amantidine, in Non-Responding or Relapsing Patients With Chronic Hepatitis C (CHC)
Sao Paulo; Research Site:
Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a(40KD)) plus Ribavirin in Patients With Chronic Hepatitis C (CHC) Genotype 1 and Human Immunodeficiency Virus-1 (HIV-1) Co-infection.
Campinas; Research Site:
Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a(40KD)) plus Ribavirin in Patients With Chronic Hepatitis C (CHC) Genotype 1 and Human Immunodeficiency Virus-1 (HIV-1) Co-infection.
Florianopolis; Research Site:
Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a(40KD)) plus Ribavirin in Patients With Chronic Hepatitis C (CHC) Genotype 1 and Human Immunodeficiency Virus-1 (HIV-1) Co-infection.
Itajaí; Research Site:
Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a(40KD)) plus Ribavirin in Patients With Chronic Hepatitis C (CHC) Genotype 1 and Human Immunodeficiency Virus-1 (HIV-1) Co-infection.
Juiz De Fora; Research Site:
Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a(40KD)) plus Ribavirin in Patients With Chronic Hepatitis C (CHC) Genotype 1 and Human Immunodeficiency Virus-1 (HIV-1) Co-infection.
Porto Alegre; Research Site:
Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a(40KD)) plus Ribavirin in Patients With Chronic Hepatitis C (CHC) Genotype 1 and Human Immunodeficiency Virus-1 (HIV-1) Co-infection.
Recife; Research Site:
Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a(40KD)) plus Ribavirin in Patients With Chronic Hepatitis C (CHC) Genotype 1 and Human Immunodeficiency Virus-1 (HIV-1) Co-infection.
Ribeirăo Preto; Research Site:
Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a(40KD)) plus Ribavirin in Patients With Chronic Hepatitis C (CHC) Genotype 1 and Human Immunodeficiency Virus-1 (HIV-1) Co-infection.
Rio De Janeiro; Research Site:
Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a(40KD)) plus Ribavirin in Patients With Chronic Hepatitis C (CHC) Genotype 1 and Human Immunodeficiency Virus-1 (HIV-1) Co-infection.
Rio Grande; Research Site:
Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a(40KD)) plus Ribavirin in Patients With Chronic Hepatitis C (CHC) Genotype 1 and Human Immunodeficiency Virus-1 (HIV-1) Co-infection.
Santo Andre; Research Site:
Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a(40KD)) plus Ribavirin in Patients With Chronic Hepatitis C (CHC) Genotype 1 and Human Immunodeficiency Virus-1 (HIV-1) Co-infection.
Santos; Research Site:
Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a(40KD)) plus Ribavirin in Patients With Chronic Hepatitis C (CHC) Genotype 1 and Human Immunodeficiency Virus-1 (HIV-1) Co-infection.
Sao Paulo; Research Site:
Hepatitis C; Chronic: A Study of Roferon-A (Interferon Alfa-2a) in Patients With Chronic Hepatitis C
Botucatu; Research Site:
Hepatitis C; Chronic: A Study of Roferon-A (Interferon Alfa-2a) in Patients With Chronic Hepatitis C
Curitiba; Research Site:
Hepatitis C; Chronic: A Study of Roferon-A (Interferon Alfa-2a) in Patients With Chronic Hepatitis C
Porto Alegre; Research Site:
Hepatitis C; Chronic: A Study of Roferon-A (Interferon Alfa-2a) in Patients With Chronic Hepatitis C
Recife; Research Site:
Hepatitis C; Chronic: A Study of Roferon-A (Interferon Alfa-2a) in Patients With Chronic Hepatitis C
Vitoria; Research Site:
Hepatitis C; Chronic: EAP (Expanded Access Program). A Study of PEGASYS (Peginterferon alfa-2a (40KD))Monotherapy and Combination Therapy With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC).
Sao Paulo; Research Site:
Hepatitis C; Chronic: HELPS study - A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC) and End-Stage Renal Disease
Brasilia; Research Site:
Hepatitis C; Chronic: HELPS study - A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC) and End-Stage Renal Disease
Porto Alegre; Research Site:
Hepatitis C; Chronic: HELPS study - A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC) and End-Stage Renal Disease
Sao Jose do Rio Preto; Research Site:
Hepatitis C; Chronic: HELPS study - A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC) and End-Stage Renal Disease
Sao Luis; Research Site:
Hepatitis C; Chronic: HELPS study - A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC) and End-Stage Renal Disease
Sao Paulo; Research Site:
Hepatitis C; Chronic: REPEAT study - A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Therapy in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Who Did Not Respond to Previous PegIntron (Peginterferon alfa-2b (12KD))/Ribavirin Combination Therapy
Rio De Janeiro; Research Site:
HIV Infections: A Study of Invirase (Saquinavir)/Ritonavir in HIV-Infected Infants and Children.
Belo Horizonte; Research Site:
HIV Infections: A Study of Invirase (Saquinavir)/Ritonavir in HIV-Infected Infants and Children.
Nova Iguaçu; Research Site:
HIV Infections: A Study of Invirase (Saquinavir)/Ritonavir in HIV-Infected Infants and Children.
Porto Alegre; Research Site:
HIV Infections: A Study of Invirase (Saquinavir)/Ritonavir in HIV-Infected Infants and Children.
Ribeirăo Preto; Research Site:
HIV Infections: A Study of Invirase (Saquinavir)/Ritonavir in HIV-Infected Infants and Children.
Salvador; Research Site:
HIV Infections: A Study of Invirase (Saquinavir)/Ritonavir in HIV-Infected Infants and Children.
Sao Paulo; Research Site:
HIV Infections: A Study to Assess the Safety of Fuzeon (Enfuvirtide) in Combination with Oral Antiretroviral Agents in Patients with Advanced Human Immunodeficiency Virus (HIV) Disease, Unable to Construct a Viable Treatment Regimen
Campinas; Research Site:
HIV Infections: A Study to Assess the Safety of Fuzeon (Enfuvirtide) in Combination with Oral Antiretroviral Agents in Patients with Advanced Human Immunodeficiency Virus (HIV) Disease, Unable to Construct a Viable Treatment Regimen
Porto Alegre; Research Site:
HIV Infections: A Study to Assess the Safety of Fuzeon (Enfuvirtide) in Combination with Oral Antiretroviral Agents in Patients with Advanced Human Immunodeficiency Virus (HIV) Disease, Unable to Construct a Viable Treatment Regimen
Rio De Janeiro; Research Site:
HIV Infections: A Study to Assess the Safety of Fuzeon (Enfuvirtide) in Combination with Oral Antiretroviral Agents in Patients with Advanced Human Immunodeficiency Virus (HIV) Disease, Unable to Construct a Viable Treatment Regimen
Salvador; Research Site:
HIV Infections: A Study to Assess the Safety of Fuzeon (Enfuvirtide) in Combination with Oral Antiretroviral Agents in Patients with Advanced Human Immunodeficiency Virus (HIV) Disease, Unable to Construct a Viable Treatment Regimen
Sao Paulo; Research Site:
HIV Infections: A Study to Collect Safety Data for Fuzeon (Enfuvirtide) in Patients With Human Immunodeficiency Virus (HIV) Infection Who Have Participated in Prior Clinical Studies of Fuzeon
Campinas; Research Site:
HIV Infections: A Study to Collect Safety Data for Fuzeon (Enfuvirtide) in Patients With Human Immunodeficiency Virus (HIV) Infection Who Have Participated in Prior Clinical Studies of Fuzeon
Porto Alegre; Research Site:
HIV Infections: A Study to Collect Safety Data for Fuzeon (Enfuvirtide) in Patients With Human Immunodeficiency Virus (HIV) Infection Who Have Participated in Prior Clinical Studies of Fuzeon
Rio De Janeiro; Research Site:
HIV Infections: A Study to Collect Safety Data for Fuzeon (Enfuvirtide) in Patients With Human Immunodeficiency Virus (HIV) Infection Who Have Participated in Prior Clinical Studies of Fuzeon
Salvador; Research Site:
HIV Infections: A Study to Collect Safety Data for Fuzeon (Enfuvirtide) in Patients With Human Immunodeficiency Virus (HIV) Infection Who Have Participated in Prior Clinical Studies of Fuzeon
Sao Paulo; Research Site:
Lupus: A Study of CellCept (Mycophenolate Mofetil) in Management of Patients With Lupus Nephritis.
Rio De Janeiro; Research Site:
Lupus: A Study of CellCept (Mycophenolate Mofetil) in Management of Patients With Lupus Nephritis.
Sao Paulo; Research Site:
Lupus: A Study of CellCept (Mycophenolate Mofetil) in Management of Patients With Lupus Nephritis.
Sorocaba; Research Site:
Systemic Lupus Erythematosus: A Study of Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus.
Belo Horizonte; Research Site:
Systemic Lupus Erythematosus: A Study of Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus.
Brasilia; Research Site:
Systemic Lupus Erythematosus: A Study of Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus.
Curitiba; Research Site:
Systemic Lupus Erythematosus: A Study of Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus.
Fortaleza; Research Site:
Systemic Lupus Erythematosus: A Study of Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus.
Goiania; Research Site:
Systemic Lupus Erythematosus: A Study of Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus.
Porto Alegre; Research Site:
Systemic Lupus Erythematosus: A Study of Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus.
Recife; Research Site:
Systemic Lupus Erythematosus: A Study of Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus.
Ribeirăo Preto; Research Site:
Systemic Lupus Erythematosus: A Study of Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus.
Sao Paulo; Research Site:
Systemic Lupus Erythematosus: A Study of Ocrelizumab in Patients With Systemic Lupus Erythematosus.
Belo Horizonte; Research Site:
Systemic Lupus Erythematosus: A Study of Ocrelizumab in Patients With Systemic Lupus Erythematosus.
Brasilia; Research Site:
Systemic Lupus Erythematosus: A Study of Ocrelizumab in Patients With Systemic Lupus Erythematosus.
Curitiba; Research Site:
Systemic Lupus Erythematosus: A Study of Ocrelizumab in Patients With Systemic Lupus Erythematosus.
Fortaleza; Research Site:
Systemic Lupus Erythematosus: A Study of Ocrelizumab in Patients With Systemic Lupus Erythematosus.
Goiania; Research Site:
Systemic Lupus Erythematosus: A Study of Ocrelizumab in Patients With Systemic Lupus Erythematosus.
Porto Alegre; Research Site:
Systemic Lupus Erythematosus: A Study of Ocrelizumab in Patients With Systemic Lupus Erythematosus.
Recife; Research Site:
Systemic Lupus Erythematosus: A Study of Ocrelizumab in Patients With Systemic Lupus Erythematosus.
Ribeirăo Preto; Research Site:
Systemic Lupus Erythematosus: A Study of Ocrelizumab in Patients With Systemic Lupus Erythematosus.
Sao Paulo; Research Site:

Bulgaria

Hepatitis B: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg-Negative Chronic Hepatitis B Virus (HBV)
Pleven; Research Site:
Hepatitis B: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg-Negative Chronic Hepatitis B Virus (HBV)
Plovdiv; Research Site:
Hepatitis B: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg-Negative Chronic Hepatitis B Virus (HBV)
Sofia; Research Site:
Hepatitis B: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg-Negative Chronic Hepatitis B Virus (HBV)
Stara Zagora; Research Site:
Hepatitis B: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg-Negative Chronic Hepatitis B Virus (HBV)
Varna; Research Site:
Hepatitis B: SOFIA-LTT Study: A Study of Intermittent Long Term Treatment With PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg Negative Chronic Hepatitis B (CHB).
Sofia; Research Site:
Hepatitis C; Chronic: A Study of Roferon-A (Interferon Alfa-2a) in Patients With Chronic Hepatitis C
Sofia; Research Site:
Hepatitis C; Chronic: EAP (Expanded Access Program). A Study of PEGASYS (Peginterferon alfa-2a (40KD))Monotherapy and Combination Therapy With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC).
Sofia; Research Site:
HIV Infections: A Study of Fuzeon (Enfuvirtide) in Patients With Advanced Human Immunodeficiency Virus-1 (HIV-1) Infection
Sofia; Research Site:
Influenza: A Study of Tamiflu (Oseltamivir) for Treatment of Influenza in Immunocompromised Patients.
Plovdiv; Research Site:
Influenza: A Study of Tamiflu (Oseltamivir) for Treatment of Influenza in Immunocompromised Patients.
Sofia; Research Site:
Pneumonia: A Study to Assess Beta-Lactam in the Treatment of Hospitalized Patients With Bacterial Pneumonia
Ruse; Research Site:
Pneumonia: A Study to Assess Beta-Lactam in the Treatment of Hospitalized Patients With Bacterial Pneumonia
Sofia; Research Site:
Soft Tissue Infections: A Study of Beta-Lactam in Hospitalized Patients With Skin and Skin Structure Infections
Pleven; Research Site:
Soft Tissue Infections: A Study of Beta-Lactam in Hospitalized Patients With Skin and Skin Structure Infections
Plovdiv; Research Site:
Soft Tissue Infections: A Study of Beta-Lactam in Hospitalized Patients With Skin and Skin Structure Infections
Sofia; Research Site:
Soft Tissue Infections: A Study of Beta-Lactam in Hospitalized Patients With Skin and Skin Structure Infections
Varna; Research Site:
Systemic Lupus Erythematosus: A Study of Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus.
Pleven; Research Site:
Systemic Lupus Erythematosus: A Study of Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus.
Sofia; Research Site:
Systemic Lupus Erythematosus: A Study of Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus.
Teteven; Research Site:
Systemic Lupus Erythematosus: A Study of Ocrelizumab in Patients With Systemic Lupus Erythematosus.
Pleven; Research Site:
Systemic Lupus Erythematosus: A Study of Ocrelizumab in Patients With Systemic Lupus Erythematosus.
Sofia; Research Site:

Canada

Allergy: A Safety and Efficacy Study of Xolair in Peanut Allergy
Ontario; Research Site
Allergy: A Safety and Efficacy Study of Xolair in Peanut Allergy
Quebec; Research Site
Celiac Disease: A Dose Ranging Study to Determine the Safety, Tolerance, and Efficacy of an Investigational Drug AT-1001 in Celiac Disease Subjects during a Gluten Challenge
Calgary, AR; Research Site
Celiac Disease: A Dose Ranging Study to Determine the Safety, Tolerance, and Efficacy of an Investigational Drug AT-1001 in Celiac Disease Subjects during a Gluten Challenge
Edmonton, AB; Research Site
Celiac Disease: A Dose Ranging Study to Determine the Safety, Tolerance, and Efficacy of an Investigational Drug AT-1001 in Celiac Disease Subjects during a Gluten Challenge
Kelowna, BC; Research Site
Celiac Disease: A Dose Ranging Study to Determine the Safety, Tolerance, and Efficacy of an Investigational Drug AT-1001 in Celiac Disease Subjects during a Gluten Challenge
Montreal, QC; Research Site
Celiac Disease: A Dose Ranging Study to Determine the Safety, Tolerance, and Efficacy of an Investigational Drug AT-1001 in Celiac Disease Subjects during a Gluten Challenge
Toronto, ON; Research Site
Celiac Disease: A Dose Ranging Study to Determine the Safety, Tolerance, and Efficacy of an Investigational Drug AT-1001 in Celiac Disease Subjects during a Gluten Challenge
Winnipeg, MB; Research Site
Cytomegalovirus Infections: A Study of Valcyte (Valganciclovir) Syrup Formulation in Pediatric Solid Organ Transplant Recipients
Edmonton, AB; Research Site:
Cytomegalovirus Infections: A Study of Valcyte (Valganciclovir) Syrup Formulation in Pediatric Solid Organ Transplant Recipients
Winnipeg, MB; Research Site:
Cytomegalovirus Infections: IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients
Edmonton, AB; Research Site:
Cytomegalovirus Infections: IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients
Hamilton, ON; Research Site:
Cytomegalovirus Infections: IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients
Montreal, QC; Research Site:
Cytomegalovirus Infections: IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients
Toronto, ON; Research Site:
Cytomegalovirus Infections: VICTOR Study - A Study of Valcyte (Valganciclovir po) Compared to Ganciclovir iv in Patients With Cytomegalovirus (CMV) Disease Who Are Solid Organ Transplant Recipients
Edmonton, AB; Research Site:
Cytomegalovirus Infections: VICTOR Study - A Study of Valcyte (Valganciclovir po) Compared to Ganciclovir iv in Patients With Cytomegalovirus (CMV) Disease Who Are Solid Organ Transplant Recipients
Toronto, ON; Research Site:
Hepatitis C; Chronic: A Study of HCV Polymerase Inhibitor Pro-Drug in Combination With PEGASYS Plus COPEGUS Compared With PEGASYS Plus COPEGUS in Patients With Chronic Hepatitis C Genotype 1 Infection.
Calgary, AB; Research Site:
Hepatitis C; Chronic: A Study of HCV Polymerase Inhibitor Pro-Drug in Combination With PEGASYS Plus COPEGUS Compared With PEGASYS Plus COPEGUS in Patients With Chronic Hepatitis C Genotype 1 Infection.
Ottawa, ON; Research Site:
Hepatitis C; Chronic: A Study of HCV Polymerase Inhibitor Pro-Drug in Combination With PEGASYS Plus COPEGUS Compared With PEGASYS Plus COPEGUS in Patients With Chronic Hepatitis C Genotype 1 Infection.
Toronto, ON; Research Site:
Hepatitis C; Chronic: A Study of HCV Polymerase Inhibitor Pro-Drug in Combination With PEGASYS Plus COPEGUS Compared With PEGASYS Plus COPEGUS in Patients With Chronic Hepatitis C Genotype 1 Infection.
Vancouver, BC; Research Site:
Hepatitis C; Chronic: A Study of Induction Dosing With PEGASYS (Peginterferon alfa-2a (40KD)) Plus Copegus in Treatment-Naive Patients With Chronic Hepatitis C.
Edmonton, AB; Research Site:
Hepatitis C; Chronic: A Study of Induction Dosing With PEGASYS (Peginterferon alfa-2a (40KD)) Plus Copegus in Treatment-Naive Patients With Chronic Hepatitis C.
Halifax, NS; Research Site:
Hepatitis C; Chronic: A Study of Induction Dosing With PEGASYS (Peginterferon alfa-2a (40KD)) Plus Copegus in Treatment-Naive Patients With Chronic Hepatitis C.
London, ON; Research Site:
Hepatitis C; Chronic: A Study of Induction Dosing With PEGASYS (Peginterferon alfa-2a (40KD)) Plus Copegus in Treatment-Naive Patients With Chronic Hepatitis C.
Ottawa, ON; Research Site:
Hepatitis C; Chronic: A Study of Induction Dosing With PEGASYS (Peginterferon alfa-2a (40KD)) Plus Copegus in Treatment-Naive Patients With Chronic Hepatitis C.
Toronto, ON; Research Site:
Hepatitis C; Chronic: A Study of Induction Dosing With PEGASYS (Peginterferon alfa-2a (40KD)) Plus Copegus in Treatment-Naive Patients With Chronic Hepatitis C.
Vancouver, BC; Research Site:
Hepatitis C; Chronic: A Study of Induction Dosing With PEGASYS (Peginterferon alfa-2a (40KD)) Plus Copegus in Treatment-Naive Patients With Chronic Hepatitis C.
Winnipeg, MB; Research Site:
Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) plus Ribavirin in Patients With Chronic Hepatitis C (CHC) Genotype 1 and Human Immunodeficiency Virus-1 (HIV-1) Co-infection, With and Without Highly Active Antiretroviral Therapy (HAART)
Edmonton, AB; Research Site:
Hepatitis C; Chronic: ACCELERATE Study - A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC) Infection.
Downsview, ON; Research Site:
Hepatitis C; Chronic: ACCELERATE Study - A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC) Infection.
Edmonton, AB; Research Site:
Hepatitis C; Chronic: ACCELERATE Study - A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC) Infection.
Mississauga, ON; Research Site:
Hepatitis C; Chronic: APPROACH study: Outcomes Assessment of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC).
Abbotsford, BC; Research Site:
Hepatitis C; Chronic: APPROACH study: Outcomes Assessment of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC).
Barrie, ON; Research Site:
Hepatitis C; Chronic: APPROACH study: Outcomes Assessment of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC).
Brampton, ON; Research Site:
Hepatitis C; Chronic: APPROACH study: Outcomes Assessment of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC).
Calgary, AB; Research Site:
Hepatitis C; Chronic: APPROACH study: Outcomes Assessment of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC).
Downsview, ON; Research Site:
Hepatitis C; Chronic: APPROACH study: Outcomes Assessment of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC).
Edmonton, AB; Research Site:
Hepatitis C; Chronic: APPROACH study: Outcomes Assessment of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC).
Hamilton, ON; Research Site:
Hepatitis C; Chronic: APPROACH study: Outcomes Assessment of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC).
Kingston, ON; Research Site:
Hepatitis C; Chronic: APPROACH study: Outcomes Assessment of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC).
London, ON; Research Site:
Hepatitis C; Chronic: APPROACH study: Outcomes Assessment of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC).
Mississauga, ON; Research Site:
Hepatitis C; Chronic: APPROACH study: Outcomes Assessment of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC).
Montreal, QC; Research Site:
Hepatitis C; Chronic: APPROACH study: Outcomes Assessment of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC).
Newmarket, ON; Research Site:
Hepatitis C; Chronic: APPROACH study: Outcomes Assessment of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC).
Oshawa, ON; Research Site:
Hepatitis C; Chronic: APPROACH study: Outcomes Assessment of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC).
Ottawa, ON; Research Site:
Hepatitis C; Chronic: APPROACH study: Outcomes Assessment of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC).
Quebec City, QC; Research Site:
Hepatitis C; Chronic: APPROACH study: Outcomes Assessment of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC).
Regina, SK; Research Site:
Hepatitis C; Chronic: APPROACH study: Outcomes Assessment of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC).
Richmond Hill, ON; Research Site:
Hepatitis C; Chronic: APPROACH study: Outcomes Assessment of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC).
St-Charles Borromee, QC; Research Site:
Hepatitis C; Chronic: APPROACH study: Outcomes Assessment of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC).
Sudbury, ON; Research Site:
Hepatitis C; Chronic: APPROACH study: Outcomes Assessment of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC).
Surrey, BC; Research Site:
Hepatitis C; Chronic: APPROACH study: Outcomes Assessment of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC).
Thunder Bay, ON; Research Site:
Hepatitis C; Chronic: APPROACH study: Outcomes Assessment of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC).
Toronto, ON; Research Site:
Hepatitis C; Chronic: APPROACH study: Outcomes Assessment of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC).
Vancouver, BC; Research Site:
Hepatitis C; Chronic: APPROACH study: Outcomes Assessment of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC).
Vernon, BC; Research Site:
Hepatitis C; Chronic: APPROACH study: Outcomes Assessment of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC).
West Vancouver, BC; Research Site:
Hepatitis C; Chronic: APPROACH study: Outcomes Assessment of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC).
Whitby, ON; Research Site:
Hepatitis C; Chronic: APPROACH study: Outcomes Assessment of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC).
Windsor, ON; Research Site:
Hepatitis C; Chronic: APPROACH study: Outcomes Assessment of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC).
Winnipeg, MB; Research Site:
Hepatitis C; Chronic: CHARIOT study - A Study of Induction Dosing with PEGASYS (Peginterferon alfa-2a (40KD)) and Ribavirin in Patients With Chronic Hepatitis C (CHC) Genotype-1
Calgary, AB; Research Site:
Hepatitis C; Chronic: CHARIOT study - A Study of Induction Dosing with PEGASYS (Peginterferon alfa-2a (40KD)) and Ribavirin in Patients With Chronic Hepatitis C (CHC) Genotype-1
Edmonton, AB; Research Site:
Hepatitis C; Chronic: CHARIOT study - A Study of Induction Dosing with PEGASYS (Peginterferon alfa-2a (40KD)) and Ribavirin in Patients With Chronic Hepatitis C (CHC) Genotype-1
Mississauga, ON; Research Site:
Hepatitis C; Chronic: CHARIOT study - A Study of Induction Dosing with PEGASYS (Peginterferon alfa-2a (40KD)) and Ribavirin in Patients With Chronic Hepatitis C (CHC) Genotype-1
Montreal, QC; Research Site:
Hepatitis C; Chronic: CHARIOT study - A Study of Induction Dosing with PEGASYS (Peginterferon alfa-2a (40KD)) and Ribavirin in Patients With Chronic Hepatitis C (CHC) Genotype-1
Vancouver, BC; Research Site:
Hepatitis C; Chronic: EAP (Expanded Access Program). A Study of PEGASYS (Peginterferon alfa-2a (40KD))Monotherapy and Combination Therapy With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC).
Abbotsford, BC; Research Site:
Hepatitis C; Chronic: EAP (Expanded Access Program). A Study of PEGASYS (Peginterferon alfa-2a (40KD))Monotherapy and Combination Therapy With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC).
Barrie, ON; Research Site:
Hepatitis C; Chronic: EAP (Expanded Access Program). A Study of PEGASYS (Peginterferon alfa-2a (40KD))Monotherapy and Combination Therapy With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC).
Brampton, ON; Research Site:
Hepatitis C; Chronic: EAP (Expanded Access Program). A Study of PEGASYS (Peginterferon alfa-2a (40KD))Monotherapy and Combination Therapy With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC).
Calgary, AB; Research Site:
Hepatitis C; Chronic: EAP (Expanded Access Program). A Study of PEGASYS (Peginterferon alfa-2a (40KD))Monotherapy and Combination Therapy With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC).
Downsview, ON; Research Site:
Hepatitis C; Chronic: EAP (Expanded Access Program). A Study of PEGASYS (Peginterferon alfa-2a (40KD))Monotherapy and Combination Therapy With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC).
Edmonton, AB; Research Site:
Hepatitis C; Chronic: EAP (Expanded Access Program). A Study of PEGASYS (Peginterferon alfa-2a (40KD))Monotherapy and Combination Therapy With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC).
Etobicoke, ON; Research Site:
Hepatitis C; Chronic: EAP (Expanded Access Program). A Study of PEGASYS (Peginterferon alfa-2a (40KD))Monotherapy and Combination Therapy With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC).
Guelph, ON; Research Site:
Hepatitis C; Chronic: EAP (Expanded Access Program). A Study of PEGASYS (Peginterferon alfa-2a (40KD))Monotherapy and Combination Therapy With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC).
Halifax, NS; Research Site:
Hepatitis C; Chronic: EAP (Expanded Access Program). A Study of PEGASYS (Peginterferon alfa-2a (40KD))Monotherapy and Combination Therapy With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC).
Hamilton, ON; Research Site:
Hepatitis C; Chronic: EAP (Expanded Access Program). A Study of PEGASYS (Peginterferon alfa-2a (40KD))Monotherapy and Combination Therapy With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC).
Hunstville; Research Site:
Hepatitis C; Chronic: EAP (Expanded Access Program). A Study of PEGASYS (Peginterferon alfa-2a (40KD))Monotherapy and Combination Therapy With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC).
Kingston, ON; Research Site:
Hepatitis C; Chronic: EAP (Expanded Access Program). A Study of PEGASYS (Peginterferon alfa-2a (40KD))Monotherapy and Combination Therapy With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC).
London, ON; Research Site:
Hepatitis C; Chronic: EAP (Expanded Access Program). A Study of PEGASYS (Peginterferon alfa-2a (40KD))Monotherapy and Combination Therapy With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC).
Mississauga, ON; Research Site:
Hepatitis C; Chronic: EAP (Expanded Access Program). A Study of PEGASYS (Peginterferon alfa-2a (40KD))Monotherapy and Combination Therapy With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC).
Moncton, NB; Research Site:
Hepatitis C; Chronic: EAP (Expanded Access Program). A Study of PEGASYS (Peginterferon alfa-2a (40KD))Monotherapy and Combination Therapy With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC).
Montreal, QC; Research Site:
Hepatitis C; Chronic: EAP (Expanded Access Program). A Study of PEGASYS (Peginterferon alfa-2a (40KD))Monotherapy and Combination Therapy With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC).
Nelson, BC; Research Site:
Hepatitis C; Chronic: EAP (Expanded Access Program). A Study of PEGASYS (Peginterferon alfa-2a (40KD))Monotherapy and Combination Therapy With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC).
New Westminster, BC; Research Site:
Hepatitis C; Chronic: EAP (Expanded Access Program). A Study of PEGASYS (Peginterferon alfa-2a (40KD))Monotherapy and Combination Therapy With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC).
Newmarket, ON; Research Site:
Hepatitis C; Chronic: EAP (Expanded Access Program). A Study of PEGASYS (Peginterferon alfa-2a (40KD))Monotherapy and Combination Therapy With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC).
North Vancouver, BC; Research Site:
Hepatitis C; Chronic: EAP (Expanded Access Program). A Study of PEGASYS (Peginterferon alfa-2a (40KD))Monotherapy and Combination Therapy With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC).
Oshawa, ON; Research Site:
Hepatitis C; Chronic: EAP (Expanded Access Program). A Study of PEGASYS (Peginterferon alfa-2a (40KD))Monotherapy and Combination Therapy With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC).
Ottawa, ON; Research Site:
Hepatitis C; Chronic: EAP (Expanded Access Program). A Study of PEGASYS (Peginterferon alfa-2a (40KD))Monotherapy and Combination Therapy With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC).
Pickering, ON; Research Site:
Hepatitis C; Chronic: EAP (Expanded Access Program). A Study of PEGASYS (Peginterferon alfa-2a (40KD))Monotherapy and Combination Therapy With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC).
Red Deer, AB; Research Site:
Hepatitis C; Chronic: EAP (Expanded Access Program). A Study of PEGASYS (Peginterferon alfa-2a (40KD))Monotherapy and Combination Therapy With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC).
Regina, SK; Research Site:
Hepatitis C; Chronic: EAP (Expanded Access Program). A Study of PEGASYS (Peginterferon alfa-2a (40KD))Monotherapy and Combination Therapy With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC).
Saskatoon, SK; Research Site:
Hepatitis C; Chronic: EAP (Expanded Access Program). A Study of PEGASYS (Peginterferon alfa-2a (40KD))Monotherapy and Combination Therapy With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC).
Scarborough, ON; Research Site:
Hepatitis C; Chronic: EAP (Expanded Access Program). A Study of PEGASYS (Peginterferon alfa-2a (40KD))Monotherapy and Combination Therapy With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC).
St John'S; Research Site:
Hepatitis C; Chronic: EAP (Expanded Access Program). A Study of PEGASYS (Peginterferon alfa-2a (40KD))Monotherapy and Combination Therapy With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC).
Summerside, PE; Research Site:
Hepatitis C; Chronic: EAP (Expanded Access Program). A Study of PEGASYS (Peginterferon alfa-2a (40KD))Monotherapy and Combination Therapy With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC).
Surrey, BC; Research Site:
Hepatitis C; Chronic: EAP (Expanded Access Program). A Study of PEGASYS (Peginterferon alfa-2a (40KD))Monotherapy and Combination Therapy With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC).
Thornhill, ON; Research Site:
Hepatitis C; Chronic: EAP (Expanded Access Program). A Study of PEGASYS (Peginterferon alfa-2a (40KD))Monotherapy and Combination Therapy With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC).
Thunder Bay, ON; Research Site:
Hepatitis C; Chronic: EAP (Expanded Access Program). A Study of PEGASYS (Peginterferon alfa-2a (40KD))Monotherapy and Combination Therapy With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC).
Toronto, ON; Research Site:
Hepatitis C; Chronic: EAP (Expanded Access Program). A Study of PEGASYS (Peginterferon alfa-2a (40KD))Monotherapy and Combination Therapy With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC).
Vancouver, BC; Research Site:
Hepatitis C; Chronic: EAP (Expanded Access Program). A Study of PEGASYS (Peginterferon alfa-2a (40KD))Monotherapy and Combination Therapy With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC).
Vancouver, ON; Research Site:
Hepatitis C; Chronic: EAP (Expanded Access Program). A Study of PEGASYS (Peginterferon alfa-2a (40KD))Monotherapy and Combination Therapy With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC).
Vernon, BC; Research Site:
Hepatitis C; Chronic: EAP (Expanded Access Program). A Study of PEGASYS (Peginterferon alfa-2a (40KD))Monotherapy and Combination Therapy With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC).
Victoria, BC; Research Site:
Hepatitis C; Chronic: EAP (Expanded Access Program). A Study of PEGASYS (Peginterferon alfa-2a (40KD))Monotherapy and Combination Therapy With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC).
Westmount, QC; Research Site:
Hepatitis C; Chronic: EAP (Expanded Access Program). A Study of PEGASYS (Peginterferon alfa-2a (40KD))Monotherapy and Combination Therapy With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC).
Whitby, ON; Research Site:
Hepatitis C; Chronic: EAP (Expanded Access Program). A Study of PEGASYS (Peginterferon alfa-2a (40KD))Monotherapy and Combination Therapy With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC).
Windsor, ON; Research Site:
Hepatitis C; Chronic: EAP (Expanded Access Program). A Study of PEGASYS (Peginterferon alfa-2a (40KD))Monotherapy and Combination Therapy With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC).
Winnipeg, MB; Research Site:
Hepatitis C; Chronic: IMPROVE Study(The Individualized Management with PEGASYS and Ribavirin Offering Viral Eradication): A Study of PEGASYS® (Peginterferon alfa-2a (40KD)) Plus Copegus (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Non-Genotype 2/3.
Mississauga, ON; Research Site:
Hepatitis C; Chronic: IMPROVE Study(The Individualized Management with PEGASYS and Ribavirin Offering Viral Eradication): A Study of PEGASYS® (Peginterferon alfa-2a (40KD)) Plus Copegus (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Non-Genotype 2/3.
Toronto, ON; Research Site:
Hepatitis C; Chronic: IMPROVE Study(The Individualized Management with PEGASYS and Ribavirin Offering Viral Eradication): A Study of PEGASYS® (Peginterferon alfa-2a (40KD)) Plus Copegus (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Non-Genotype 2/3.
London, ON; Research Site:
Hepatitis C; Chronic: IMPROVE Study(The Individualized Management with PEGASYS and Ribavirin Offering Viral Eradication): A Study of PEGASYS® (Peginterferon alfa-2a (40KD)) Plus Copegus (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Non-Genotype 2/3.
Abbotsford, BC; Research Site:
Hepatitis C; Chronic: IMPROVE Study(The Individualized Management with PEGASYS and Ribavirin Offering Viral Eradication): A Study of PEGASYS® (Peginterferon alfa-2a (40KD)) Plus Copegus (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Non-Genotype 2/3.
Halifax, NS; Research Site:
Hepatitis C; Chronic: IMPROVE Study(The Individualized Management with PEGASYS and Ribavirin Offering Viral Eradication): A Study of PEGASYS® (Peginterferon alfa-2a (40KD)) Plus Copegus (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Non-Genotype 2/3.
Vancouver, BC; Research Site:
Hepatitis C; Chronic: IMPROVE Study(The Individualized Management with PEGASYS and Ribavirin Offering Viral Eradication): A Study of PEGASYS® (Peginterferon alfa-2a (40KD)) Plus Copegus (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Non-Genotype 2/3.
Vernon, BC; Research Site:
Hepatitis C; Chronic: IMPROVE Study(The Individualized Management with PEGASYS and Ribavirin Offering Viral Eradication): A Study of PEGASYS® (Peginterferon alfa-2a (40KD)) Plus Copegus (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Non-Genotype 2/3.
Calgary, AB; Research Site:
Hepatitis C; Chronic: IMPROVE Study(The Individualized Management with PEGASYS and Ribavirin Offering Viral Eradication): A Study of PEGASYS® (Peginterferon alfa-2a (40KD)) Plus Copegus (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Non-Genotype 2/3.
Victoria, BC; Research Site:
Hepatitis C; Chronic: IMPROVE Study(The Individualized Management with PEGASYS and Ribavirin Offering Viral Eradication): A Study of PEGASYS® (Peginterferon alfa-2a (40KD)) Plus Copegus (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Non-Genotype 2/3.
Hamilton, ON; Research Site:
Hepatitis C; Chronic: IMPROVE Study(The Individualized Management with PEGASYS and Ribavirin Offering Viral Eradication): A Study of PEGASYS® (Peginterferon alfa-2a (40KD)) Plus Copegus (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Non-Genotype 2/3.
Montreal, QC; Research Site:
Hepatitis C; Chronic: IMPROVE Study(The Individualized Management with PEGASYS and Ribavirin Offering Viral Eradication): A Study of PEGASYS® (Peginterferon alfa-2a (40KD)) Plus Copegus (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Non-Genotype 2/3.
Edmonton, AB; Research Site:
Hepatitis C; Chronic: IMPROVE Study(The Individualized Management with PEGASYS and Ribavirin Offering Viral Eradication): A Study of PEGASYS® (Peginterferon alfa-2a (40KD)) Plus Copegus (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Non-Genotype 2/3.
Ottawa, ON; Research Site:
Hepatitis C; Chronic: IMPROVE Study(The Individualized Management with PEGASYS and Ribavirin Offering Viral Eradication): A Study of PEGASYS® (Peginterferon alfa-2a (40KD)) Plus Copegus (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Non-Genotype 2/3.
Saskatoon, SK; Research Site:
Hepatitis C; Chronic: IMPROVE Study(The Individualized Management with PEGASYS and Ribavirin Offering Viral Eradication): A Study of PEGASYS® (Peginterferon alfa-2a (40KD)) Plus Copegus (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Non-Genotype 2/3.
Kingston, ON; Research Site:
Hepatitis C; Chronic: REPEAT study - A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Therapy in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Who Did Not Respond to Previous PegIntron (Peginterferon alfa-2b (12KD))/Ribavirin Combination Therapy
Vancouver, BC; Research Site:
Hepatitis C; Chronic: REPEAT study - A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Therapy in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Who Did Not Respond to Previous PegIntron (Peginterferon alfa-2b (12KD))/Ribavirin Combination Therapy
Toronto, ON; Research Site:
HIV Infections: A Study Comparing the Efficacy and Safety of Once-Daily Fuzeon (Enfuvirtide) Dosing Versus the Currently Recommended Twice-Daily Dosing in Human Immunodeficiency Virus-Type 1 (HIV-1) Infected Patients
Montreal, QC; Research Site:
HIV Infections: A Study Comparing the Efficacy and Safety of Once-Daily Fuzeon (Enfuvirtide) Dosing Versus the Currently Recommended Twice-Daily Dosing in Human Immunodeficiency Virus-Type 1 (HIV-1) Infected Patients
Toronto, ON; Research Site:
HIV Infections: A Study of Saquinavir/Ritonavir in Liver-Impaired Patients With HIV Infection.
Ottawa, ON; Research Site:
HIV Infections: A Study of Saquinavir/Ritonavir in Liver-Impaired Patients With HIV Infection.
Toronto, ON; Research Site:
HIV Infections: A Study to Assess the Safety of Fuzeon (Enfuvirtide) in Combination with Oral Antiretroviral Agents in Patients with Advanced Human Immunodeficiency Virus (HIV) Disease, Unable to Construct a Viable Treatment Regimen
Calgary, AB; Research Site:
HIV Infections: A Study to Assess the Safety of Fuzeon (Enfuvirtide) in Combination with Oral Antiretroviral Agents in Patients with Advanced Human Immunodeficiency Virus (HIV) Disease, Unable to Construct a Viable Treatment Regimen
Edmonton, AB; Research Site:
HIV Infections: A Study to Assess the Safety of Fuzeon (Enfuvirtide) in Combination with Oral Antiretroviral Agents in Patients with Advanced Human Immunodeficiency Virus (HIV) Disease, Unable to Construct a Viable Treatment Regimen
Halifax, NS; Research Site:
HIV Infections: A Study to Assess the Safety of Fuzeon (Enfuvirtide) in Combination with Oral Antiretroviral Agents in Patients with Advanced Human Immunodeficiency Virus (HIV) Disease, Unable to Construct a Viable Treatment Regimen
Montreal, QC; Research Site:
HIV Infections: A Study to Assess the Safety of Fuzeon (Enfuvirtide) in Combination with Oral Antiretroviral Agents in Patients with Advanced Human Immunodeficiency Virus (HIV) Disease, Unable to Construct a Viable Treatment Regimen
Ottawa, ON; Research Site:
HIV Infections: A Study to Assess the Safety of Fuzeon (Enfuvirtide) in Combination with Oral Antiretroviral Agents in Patients with Advanced Human Immunodeficiency Virus (HIV) Disease, Unable to Construct a Viable Treatment Regimen
Saskatoon, SK; Research Site:
HIV Infections: A Study to Assess the Safety of Fuzeon (Enfuvirtid